Literature DB >> 29719120

Hepatoblastoma in patients with molecularly proven familial adenomatous polyposis: Clinical characteristics and rationale for surveillance screening.

Angela D Trobaugh-Lotrario1, Dolores López-Terrada2, Peng Li2, James H Feusner3.   

Abstract

Familial adenomatous polyposis (FAP) due to APC mutation is associated with an increased risk of hepatoblastoma. All cases of hepatoblastoma in patients with FAP reported in the literature were reviewed. One hundred and nine patients were identified. Thirty-five patients (of 49 with data) were diagnosed with hepatoblastoma prior to a later diagnosis of FAP (often in association with advanced colorectal carcinoma), emphasizing a need to identify patients earlier with germline APC mutations for early colorectal carcinoma screening. Hepatoblastoma may present at birth, and screening for hepatoblastoma in infancy in families with FAP prior to APC mutation testing results may be warranted.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  APC; familial adenomatous polyposis; hepatoblastoma

Mesh:

Year:  2018        PMID: 29719120     DOI: 10.1002/pbc.27103

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  9 in total

1.  American College of Radiology LI-RADS in pediatric patients: the good, the bad, and the future.

Authors:  Gary R Schooler
Journal:  Pediatr Radiol       Date:  2019-05-08

2.  β-Catenin mutations as determinants of hepatoblastoma phenotypes in mice.

Authors:  Weiqi Zhang; Jennifer Meyfeldt; Huabo Wang; Sucheta Kulkarni; Jie Lu; Jordan A Mandel; Brady Marburger; Ying Liu; Joanna E Gorka; Sarangarajan Ranganathan; Edward V Prochownik
Journal:  J Biol Chem       Date:  2019-10-09       Impact factor: 5.157

3.  Gastrointestinal Polyposis in Pediatric Patients.

Authors:  Suzanne P MacFarland; Kristin Zelley; Bryson W Katona; Benjamin J Wilkins; Garrett M Brodeur; Petar Mamula
Journal:  J Pediatr Gastroenterol Nutr       Date:  2019-09       Impact factor: 2.839

4.  Case Report of Congenital Hepatoblastoma With the Onset at 30-Weeks' Gestation.

Authors:  Zheng Yan; Wei Bai; Li Li; Shuo Li; Ying Hua; Xiao-Xiao Zhang; Xin-Lin Hou
Journal:  Front Pediatr       Date:  2022-07-01       Impact factor: 3.569

5.  Molecular Mechanisms of Hepatoblastoma.

Authors:  Yi Zhang; Antonio Solinas; Stefano Cairo; Matthias Evert; Xin Chen; Diego F Calvisi
Journal:  Semin Liver Dis       Date:  2021-01-20       Impact factor: 6.115

6.  APC germline hepatoblastomas demonstrate cisplatin-induced intratumor tertiary lymphoid structures.

Authors:  Guillaume Morcrette; Theo Z Hirsch; Elise Badour; Jill Pilet; Stefano Caruso; Julien Calderaro; Yoann Martin; Sandrine Imbeaud; Eric Letouzé; Sandra Rebouissou; Sophie Branchereau; Sophie Taque; Christophe Chardot; Catherine Guettier; Jean-Yves Scoazec; Monique Fabre; Laurence Brugières; Jessica Zucman-Rossi
Journal:  Oncoimmunology       Date:  2019-03-28       Impact factor: 8.110

7.  ALKBH5 Gene Polymorphisms and Hepatoblastoma Susceptibility in Chinese Children.

Authors:  Hui Ren; Zhen-Jian Zhuo; Fei Duan; Yong Li; Zhonghua Yang; Jiao Zhang; Jiwen Cheng; Suhong Li; Li Li; Jianlei Geng; Zhiguang Zhang; Jing He; Huizhong Niu
Journal:  J Oncol       Date:  2021-03-19       Impact factor: 4.375

Review 8.  Hepatoblastoma in molecularly defined, congenital diseases.

Authors:  Gunther Nussbaumer; Martin Benesch
Journal:  Am J Med Genet A       Date:  2022-04-28       Impact factor: 2.578

9.  Health Status in Long-Term Survivors of Hepatoblastoma.

Authors:  Bożenna Dembowska-Bagińska; Jolanta Więckowska; Agnieszka Brożyna; Ewa Święszkowska; Hor Ismail; Dorota Broniszczak-Czyszek; Marek Stefanowicz; Wiesława Grajkowska; Piotr Kaliciński
Journal:  Cancers (Basel)       Date:  2019-11-11       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.